


DOCKET NO.: ISPT1010 (PTS-0070US.P1)**PATENT****REMARKS**

Claims 1-115 were pending. Upon entry of this amendment, claims 1-8, 22-25, 33, 37-44, 47-54, 64-67, 70, 71, 77, 81-88 and 91-121 will be pending. Claim 1 is amended to specify the nucleic acid sequence of the target and to specify that the compound comprises at least an 8-nucleobase portion of SEQ ID NO: 189 or 446. The amendments find basis in the specification and claims as originally filed, such as, for example, in the specification at pages 27-28, Example 17 beginning on page 88 and Examples 29-30 beginning on page 115, and in original claims 26 and 92. Claims 70 and 71 are amended to specify SEQ ID NO: 285. Claim 92 is amended to remove SEQ ID NOs 233, 443, 444, 447 and 448 and to add SEQ ID NOs 451 and 452. The amendment find basis, for example, in Examples 29-30, beginning on page 115 of the specification. New claims 116-121 find basis in the specification and claims as originally filed. Thus, no new matter has been added. Applicants reserve the right to file subsequent applications claiming the canceled subject matter.

An early Office Action on the merits is earnestly solicited. The Examiner is invited to contact Applicants' undersigned representative at the number below if there are any questions regarding Applicants' claimed invention.

Respectfully submitted,


Jodi L. Connolly, Ph.D.
Registration No. 54,044

Date: October 27, 2005

ISIS Pharmaceuticals, Inc.
1896 Rutherford Rd.
Carlsbad, CA 92008
Telephone: (760) 603-2777
Facsimile: (760) 603-3820